Effects of of PRRT2 mutations on therapy with Anti-epilepsy drugs for epilepsy in Chinese Han patients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15005832

Enrollment

Unknown

Registered

2015-01-13

Start date

2015-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

Case series:Anti-epilepsy drugs

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1) Chinese Han children with epilepsy, clinical diagnosis more than six months; 2) single Anti-epilepsy drug treatment in therapeutic process; 3) Anti-epilepsy drug was reselected for poor effect; 4) Treatment effect is good after drug reselection.

Exclusion criteria

Exclusion criteria: With severe organic diseases such as blood disease, liver or kidney dysfunction; suffering from any Progressive diseases such as cancer; suffering from any organic brain or central nervous system diseases.

Design outcomes

Primary

Measure	Time frame
PRRT2 genetic polymorphisms;	—

Contacts

Public ContactZhongdong Lin

wzlzhd@163.com+86 13957713578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026